Less participation by the national institute of allergy and infectious diseases, or niaid, the israeli innovation authority, or iia, and horizon europe
14
123
30
-356*
Research and development expenses, net
3,962
3,826
3,931
4,180*
General and administrative expenses
2,630
2,766
2,534
2,452*
Operating loss
-6,536
-6,506
-6,350
-6,578*
Financial income (expenses), net
-
-
-
-51*
Other financial income (expenses), net
593
-143
439
-
Interest expenses
237
231
229
-1,486*
Total financial income (expenses), net
356
-374
210
1,435*
Loss before taxes
-6,180
-6,880
-6,140
-5,143*
Tax benefit
-8
-8
-8
-1*
Net loss
-6,172
-6,872
-6,132
-5,142*
Net loss attributed to non-controlling interest
-624
-329
-282
-205*
Net loss attributed to shareholders
-5,548
-6,543
-5,850
-4,937
Basic EPS
-0.55
-0.71
-0.65
-0.684
Diluted EPS
-0.55
-0.71
-0.65
-0.684
Basic Average Shares
10,054,803
9,260,439
8,995,635
7,214,750
Diluted Average Shares
10,054,803
9,260,439
8,995,635
7,214,750
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.